Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

被引：7
|
作者：
Elsbernd, Paul M. [1 ]
Carter, Jonathan L. [1 ]
机构：
[1] Mayo Clin, Dept Neurol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA
来源：
BIOLOGICS-TARGETS & THERAPY | 2021年 / 15卷
关键词：
monoclonal antibodies; multiple sclerosis; relapsing; progressive; review; NATALIZUMAB ANTIBODIES; INTERFERON BETA-1A; CONTROLLED TRIAL; RISK; ALEMTUZUMAB; RITUXIMAB; OCRELIZUMAB; PLACEBO; MECHANISMS; SAFETY;
D O I：
10.2147/BTT.S267273
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple sclerosis due to their potent efficacy, convenient dosing schedules, and well-defined side effect profiles. Each therapy has unique risks and benefits associated with its specific mechanism of action which ultimately guides clinical decision-making for individual patients. This review will summarize the mechanisms of action, evidence leading to their approval, and clinically relevant considerations for each of the current monoclonal antibody therapies approved for the treatment of multiple sclerosis.
引用
收藏
页码：255 / 263
页数：9
相关论文
共 50 条
  • [21] CD38 Monoclonal Antibody Therapies for Multiple Myeloma
    Wong, Sandy W.
    Comenzo, Raymond L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (11): : 635 - 645
  • [22] Monoclonal Antibody-Based Therapies in Human Multiple Myeloma
    Tai, Yu-Tzu
    Fulciniti, Mariateresa
    Tassone, Pierfrancesco
    Neri, Paolo
    Mitsiades, Constantine C.
    Hideshima, Teru
    Chauhan, Darminder
    Richardson, Paul G.
    Anderson, Kenneth C.
    Munshi, Nikhil C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S22 - S23
  • [23] Antibody-mediated cell depletion therapies in multiple sclerosis
    Mariottini, Alice
    Muraro, Paolo A.
    Luenemann, Jan D.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [24] A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine
    Reuter, Uwe
    HEADACHE, 2018, 58 : 48 - 59
  • [25] Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis
    Xu Zhang
    Raymond Hupperts
    Marc De Baets
    Immunologic Research, 2003, 28 : 61 - 78
  • [26] Monoclonal antibody therapy in experimental allergic encephalomyelitis and multiple sclerosis
    Zhang, X
    Hupperts, R
    De Baets, M
    IMMUNOLOGIC RESEARCH, 2003, 28 (01) : 61 - 78
  • [27] Challenges of Monoclonal Antibody Therapy in Multiple Sclerosis: Case Study
    Kok, H. T.
    Ng, C. F.
    Tan, H. J.
    Remli, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (09) : NP91 - NP92
  • [28] Progressive Multifocal Leukoencephalopathy (PML) With Anti-CD20 and Other Monoclonal Antibody (mAb) Therapies in Multiple Sclerosis
    Sharma, Kanika
    Srivastava, Samiksha
    Jena, Anek
    Kakara, Mihir
    Sriwastava, Shitiz
    Daimee, Maha
    Xu, Jian
    NEUROLOGY, 2023, 100 (17)
  • [29] Antiviral monoclonal antibody therapies
    Florez, Catalina
    Haslwanter, Denise
    Jangra, Rohit K.
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [30] Monoclonal antibody therapies for lymphomas
    Foon, KA
    CANCER JOURNAL, 2000, 6 (05): : 273 - 278
12345